Tag: Hla a 02 01

Explore our medication guides and pharmacology articles within this category.

What is Tebentafusp? A First-in-Class Immunotherapy for Uveal Melanoma

Oct 6, 2025 •

3 min read

Tebentafusp was the first-in-class T-cell receptor therapeutic to be approved by the FDA, representing a significant breakthrough in cancer treatment. This innovative immunotherapy, also known by its brand name Kimmtrak, is a targeted therapy for adults with unresectable or metastatic uveal melanoma.

What is Kimmtrak? An In-depth Look at Tebentafusp for Uveal Melanoma

Oct 5, 2025 •

3 min read

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) as the first T-cell receptor (TCR) therapeutic for a solid tumor, representing a significant advancement in oncology. So, **what is kimmtrak?** This bispecific fusion protein is indicated for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.